Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19862815rdf:typepubmed:Citationlld:pubmed
pubmed-article:19862815lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0007134lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C1516119lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C1879847lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:19862815lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:19862815pubmed:issue1lld:pubmed
pubmed-article:19862815pubmed:dateCreated2010-1-18lld:pubmed
pubmed-article:19862815pubmed:abstractTextThe objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC).lld:pubmed
pubmed-article:19862815pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:languageenglld:pubmed
pubmed-article:19862815pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:citationSubsetAIMlld:pubmed
pubmed-article:19862815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19862815pubmed:statusMEDLINElld:pubmed
pubmed-article:19862815pubmed:monthJanlld:pubmed
pubmed-article:19862815pubmed:issn0008-543Xlld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:NgChaanClld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:TamboliPheroz...lld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:WrightJohn...lld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:AparicioAnaAlld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:PagliaroLance...lld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:WarnekeCarla...lld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:JohnsonMarcel...lld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:TannirNizar...lld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:JonaschEricElld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:CornPaulPlld:pubmed
pubmed-article:19862815pubmed:authorpubmed-author:AsheRobynne...lld:pubmed
pubmed-article:19862815pubmed:copyrightInfoCopyright 2010 American Cancer Society.lld:pubmed
pubmed-article:19862815pubmed:issnTypePrintlld:pubmed
pubmed-article:19862815pubmed:day1lld:pubmed
pubmed-article:19862815pubmed:volume116lld:pubmed
pubmed-article:19862815pubmed:ownerNLMlld:pubmed
pubmed-article:19862815pubmed:authorsCompleteYlld:pubmed
pubmed-article:19862815pubmed:pagination57-65lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:meshHeadingpubmed-meshheading:19862815...lld:pubmed
pubmed-article:19862815pubmed:year2010lld:pubmed
pubmed-article:19862815pubmed:articleTitleUpfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.lld:pubmed
pubmed-article:19862815pubmed:affiliationDepartment of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. ejonasch@mdanderson.orglld:pubmed
pubmed-article:19862815pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19862815pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:19862815pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:19862815pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19862815pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19862815lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19862815lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19862815lld:pubmed